Anyu Aixin Completes New Round of Financing Led by Beijing Medical and Health Industry Investment Fund to Accelerate Commercialization of All-Optical Ultrasound Technology

Ace Cardio (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as “Ace Cardio”) has officially announced the completion of a new round of financing amounting to tens of millions of RMB. This round was led by the Beijing Pharmaceutical and Health Industry Investment Fund, with participation from renowned institutions including Zhongguancun Capital, Tongzheng Fund, and Junling Investment. The funds raised will be primarily used to accelerate the R&D iteration, clinical trials, regulatory registration, and commercialization layout of the company’s core product—an interventional ultrasound imaging system based on all-optical ultrasound technology.

The successful completion of this funding round marks the dual endorsement of Ace Cardio’s disruptive technology—fully optical ultrasound imaging—by both government-guided funds and market-oriented capital.

As the lead investor in this round, the Beijing Medical and Health Industry Investment Fund is a municipal government investment fund established by Beijing to accelerate innovation in the medical and health industries and promote the development of new quality productive forces, with a focus on key areas such as innovative drugs and innovative medical devices. This investment not only affirms Ace Cardio’s technological strength and commercial prospects but also represents a strategic move by Beijing to position itself in the frontier sector of high-end medical devices and support the growth of local innovative enterprises.

Ace Cardio – Committed to Becoming the Definer and Leader of Global All-Optical Interventional Ultrasound Imaging Technology

Ace Cardio, established in August 2022, is a high-tech enterprise specializing in the precise diagnosis and treatment of pan-vascular interventional procedures. The company is dedicated to building the next-generation interventional imaging platform based on all-optical ultrasound principles. Headquartered in Zhongguancun, Beijing, and serving the global market, Ace Cardio aims to address the long-standing pain points of traditional intravascular imaging technologies through disruptive technological innovations, striving to become a benchmark enterprise for domestic substitution and original innovation in high-end medical devices.

Ace Cardio’s core technology originates from Beijing AeronauticsAerospaceProfessor Wang Pu’s team at the university has been dedicated for many years to the research and application of all-optical ultrasound imaging, a disruptive technology. This technology breaks through the physical limitations of traditional piezoelectric ultrasound, featuring ultra-wide bandwidth and high sensitivity, thereby achieving a perfect integration of micron-level high resolution for intravascular imaging and deep tissue penetration. In 2023, this technology was selected as one of the Top 10 Global Ultrasound Innovations by Science magazine, drawing significant attention from the international academic community.

Its core product, the all-optical intravascular ultrasound (IVUS) system, is designed to serve as the optimal “third eye” for precise interventional treatment of vascular diseases. It enables physicians to accurately assess vessel wall structure, plaque characteristics, and stenosis severity during preoperative, intraoperative, and postoperative phases, thereby optimizing treatment strategies, improving surgical success rates, ultimately benefiting a broad patient population, and contributing to the Healthy China 2030 initiative. Ace Cardio’s technological approach is at the forefront globally, striving to achieve a leap from “following” to “leading.”

Equipment - Operating Room Cart (Left) PIU - Bedside Control Unit (Center) Catheter - Rapid Exchange Catheter/OTW Catheter (Right)

Leveraging its outstanding technological innovation, Ace Cardio has successively obtained qualifications such as National High-Tech Enterprise and Beijing “Specialized, Refined, Differential, and Innovative” SME, and has won numerous awards in prestigious competitions including the HICOOL Global Entrepreneurship Competition.

The Beijing Pharmaceutical and Health Industry Investment Fund stated, “Ace Cardio’s all-optical ultrasound technology is at the global forefront, representing a typical example of ‘hard tech’ innovation. We are optimistic about its significant clinical value and market potential. As an important component of Beijing’s pharmaceutical and health industry ecosystem, we will actively facilitate industrial resource connections for Ace Cardio to jointly promote the high-quality development of the capital’s pharmaceutical and health industry.”

Currently, Beijing is making every effort to build a world-class hub for biomedical innovation. By establishing a cluster of pharmaceutical and health industry funds with a total scale of RMB 20 billion and introducing a series of measures such as the “32 Articles on Innovative Pharmaceuticals,” the city provides full-chain support for innovative enterprises, covering research and development, clinical trials, and industrialization.

As a homegrown innovative enterprise, Ace Cardio is seizing unprecedented opportunities for development. Xi Weiling, Co-Founder and CEO, stated, “We are deeply honored to receive joint investment from the Beijing Pharmaceutical and Health Industry Investment Fund, as well as from both new and existing investors in this and previous rounds. This capital infusion has provided strong momentum for the R&D, regulatory approval, and commercialization of our core products. We thank ‘patient capital’ for its long-term trust, which allows us to focus wholeheartedly on refining our products. Our goal is clear: to serve precision medicine with innovative technology. We are committed to becoming a global leader in precise diagnosis and treatment across the pan-vascular field, contributing ‘Ace Cardio’s strength’ to China’s high-end medical device industry.”

Beijing Shunxi Private Equity Fund Management Co., Ltd. (“Shunxi Fund”) is a full-lifecycle investment platform under Beijing State-owned Capital Management & Operation Group (Beijing Guoguan), with a strategic focus on investing in emerging strategic industries. Since its establishment, Shunxi Fund has evolved from a venture capital platform positioned to “invest early, invest small, invest in technology, and invest in Beijing” under Beijing Guoguan into a comprehensive full-lifecycle investment platform. By fostering strong collaborative relationships with numerous universities and research institutes, new-type R&D institutions, municipal- and district-level state-owned capital funds, market-oriented general partners (GPs), leading enterprises in industrial chains, and relevant government authorities, the company has continuously built a multi-dimensional synergistic support system. This has enabled Shunxi Fund to accumulate high-quality project resources with unique advantages and diverse channels, as well as robust post-investment value-added capabilities.

Shunxi Fund strictly adheres to the principles of “government guidance, market-based operations, scientific decision-making, and risk prevention” in its fund management. Closely aligning with the national strategic layout for high-end and cutting-edge industries, efforts to overcome “chokepoint” technologies, and the needs for leading industrial innovation, the Fund integrates its own development into Beijing’s high-quality development process. It is committed to driving innovative breakthroughs in key core technologies within the industry and has achieved remarkable results in nurturing high-potential enterprises to develop in Beijing. The Fund has also delivered strong performance in facilitating the commercialization of scientific and technological achievements in Beijing’s four major industries, supporting the attraction and landing of high-quality projects, and fostering the cultivation and growth of emerging industries.

Zhongguancun Capital is a wholly-owned subsidiary of Zhongguancun Development Group. Originating from the Group’s Major Projects Department and Investment Department, it serves as the Group’s capital platform for supporting the development of technological innovation industries. Since 2010, it has accumulated nearly 15 years of investment experience, with assets under management (AUM) reaching RMB 58.2 billion. Its fund product lineup includes Scientist Funds, Angel and Venture Capital (VC) Funds, Private Equity (PE) Funds, Strategic Funds, M&A Funds, Equity-Debt Linkage Funds, Fund of Funds (FoF), and Secondary (S) Funds. To date, its fund portfolio has invested in over 4,200 companies, among which 210 have completed initial public offerings (IPOs). It has cumulatively invested in 1,395 “Specialized, Refined, Differential, and Innovative” (SRDI) enterprises and 103 unicorn companies.

Beijing Tongzheng Private Equity Fund Management Co., Ltd., established in 2021, is a subsidiary of Beijing Tongzhou Industrial Service Co., Ltd. Tongzheng Fund focuses on the digital economy and advanced manufacturing, while continuously expanding into other key industries supported by the Sub-Center, including pharmaceuticals and healthcare, artificial intelligence, technology services, green development, finance, design and performing arts, and culture, commerce, tourism, and sports. It is committed to incubating and nurturing a cohort of technology-driven enterprises with internationally leading technical capabilities for the Sub-Center, thereby establishing a specialized, market-oriented fund management platform exclusive to the Sub-Center.

Junling Investment is committed to propelling Chinese innovation onto the global stage, with a primary focus on enterprises driven by innovative technologies. Since its inception, leveraging independent in-depth research to gain insights into the development trends of core industry segments and drawing upon its shareholders’ profound industrial background, Junling Investment has participated from the early stages in investments in well-known projects such as Moore Threads, Andekeming, Aochuang Photonics, Zhipingfang, and Jiatuo New Energy. Adhering to the strategy of investing early, investing in small-scale ventures, and focusing on innovative technologies, Junling Investment advocates a “deep engagement” investment model. It selectively provides substantial empowerment to its portfolio companies and continues to increase its stakes, pursuing high investment returns that surpass those of its peers.